Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-polylactide

Biomaterials

Volumn 35, Issue 5, 2014, Pages 1686-1695

  Chen, Wei Lin ^a,b   Liu, Shih Jen ^b,c   Leng, Chih Hsiang ^b,c   Chen, Hsin Wei ^b,c   Chong, Pele ^b,c   Huang, Ming Hsi ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bioresorbable polymer; Cancer immunotherapy; Emulsion disintegration; Tumor associated antigen; Vaccine adjuvant

Indexed keywords

ALIPHATIC COMPOUNDS; ANTIGENS; DISEASES; DISINTEGRATION; EMULSIONS; ETHYLENE GLYCOL; IMMUNE SYSTEM; PEPTIDES; PHASE SEPARATION; POLYESTERS; POLYETHYLENE GLYCOLS; POLYOLS; T-CELLS; TUMORS; VACCINES;

BIORESORBABLE POLYMERS; CANCER IMMUNOTHERAPY; DISINTEGRATION CHARACTERISTICS; LOW MOLECULAR WEIGHT; OIL-IN-WATER EMULSIONS; PHOSPHATE BUFFER SALINES; VACCINE ADJUVANTS; WATER DELIVERY SYSTEMS;

EMULSIFICATION;

ALUMINUM POTASSIUM SULFATE; DRUG CARRIER; MACROGOL; PHOSPHATE BUFFERED SALINE; POLYLACTIDE; SQUALANE; UNCLASSIFIED DRUG; WART VIRUS VACCINE; WATER;

ANIMAL EXPERIMENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; HYDROLYSIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NANOEMULSION; NONHUMAN; PHASE SEPARATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ROOM TEMPERATURE; SEPARATION TECHNIQUE; SURFACE PROPERTY;

BIORESORBABLE POLYMER; CANCER IMMUNOTHERAPY; EMULSION DISINTEGRATION; TUMOR-ASSOCIATED ANTIGEN; VACCINE ADJUVANT;

ANIMALS; BIOCOMPATIBLE MATERIALS; EMULSIONS; HYDROLYSIS; IMMUNOTHERAPY; LACTATES; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SQUALENE; T-LYMPHOCYTES; WATER;

EID: 84890157277     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.004     Document Type: Article

References (38)

1. Rappuoli R., Dormitzer P.R. Influenza: options to improve pandemic preparation. Science 2012, 336:1531-1533.
2. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
3. Huang R.Y., Yu Y.L., Cheng W.C., OuYang C.N., Fu E., Chu C.L. Immunosuppressive effect of quercetin on dendritic cell activation and function. JImmunol 2010, 184:6815-6821.
4. Song Y.C., Chou A.H., Homhuan A., Huang M.H., Chiang S.K., Shen K.Y., et al. Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway invivo. JLeukoc Biol 2011, 90:323-332.
5. Miconnet I., Coste I., Beermann F., Haeuw J.F., Cerottini J.C., Bonnefoy J.Y., et al. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. JImmunol 2001, 166:4612-4619.
6. Shen S.S., Yang Y.W. Antigen delivery for cross priming via the emulsion vaccine adjuvants. Vaccine 2012, 30:1560-1571.
7. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672.
8. Seubert A., Monaci E., Pizza M., O'Hagan D.T., Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. JImmunol 2008, 180:5402-5412.
9. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105:10501-10506.
10. Huang M.H., Chou A.H., Lien S.P., Chen H.W., Huang C.Y., Chen W.W., et al. Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone). JBiomed Mater Res B Appl Biomater 2009, 90:832-841.
11. Huang M.H., Huang C.Y., Lien S.P., Siao S.Y., Chou A.H., Chen H.W., et al. Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm Res 2009, 26:1856-1862.
12. Huang M.H., Huang C.Y., Lin S.C., Chen J.H., Ku C.C., Chou A.H., et al. Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect 2009, 11:654-660.
13. Huang M.H., Lin S.C., Hsiao C.H., Chao H.J., Yang H.R., Liao C.C., et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 2010, 5:e12279.
14. Babensee J.E., Anderson J.M., McIntire L.V., Mikos A.G. Host response to tissue engineered devices. Adv Drug Deliv Rev 1998, 33:111-139.
15. Allison A.C. Squalene and squalane emulsions as adjuvants. Methods 1999, 19:87-93.
16. Salager J.L., Loaiza-Maldonado I., Minana-Perez M., Silva F. Surfactant-oil-water systems near the affinity inversion part I: relationship between equilibrium phase behavior and emulsion type and stability. JDispers Sci Technol 1982, 3:279-292.
17. Ladasiu C., Choudhury N.R., Dutta N., Voelcker N.H. MALDI-TOF MS and DIOS-MS investigation of the degradation and discoloration of poly(ethylene terephthalate). Macromolecules 2006, 39:7872-7881.
18. Clifford G.M., Smith J.S., Aguado T., Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89:101-105.
19. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23:2242-2249.
20. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
21. Grizzi I., Garreau H., Li S., Vert M. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials 1995, 16:305-311.
22. Akagi T., Higashi M., Kaneko T., Kida T., Akashi M. Hydrolytic and enzymatic degradation of nanoparticles based on amphiphilic poly(γ-glutamic acid)-graft-l-phenylalanine copolymers. Biomacromolecules 2006, 7:297-303.
23. Huang M.H., Li S., Vert M. Synthesis and degradation of PLA-PCL-PLA triblock copolymer prepared by successive polymerization of ε-caprolactone and DL-lactide. Polymer 2004, 45:8675-8681.
24. Stefani M., Coudane J., Vert M. Invitro ageing and degradation of PEG-PLA diblock copolymer-based nanoparticles. Polym Degrad Stab 2006, 91:2554-2559.
25. Ndazi B.S., Karlsson S. Characterization of hydrolytic degradation of polylactic acid/rice hulls composites in water at different temperatures. Express Polym Lett 2011, 5:119-131.
26. Huang M.H., Leng C.H., Liu S.J., Chen H.W., Sia C., Chong P. Vaccine delivery systems based on amphiphilic bioresorbable polymers and their role in vaccine immunogenicity. Immunogenicity 2011, 61-90. Nova Science Publishers, New York. C.J. Villanueva (Ed.).
27. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
28. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22:411-416.
29. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
30. Anderson R.B., Cianciolo G.J., Kennedy M.N., Pizzo S.V. α2-Macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism. JLeukoc Biol 2008, 83:381-392.
31. Knutson K.L., Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54:721-728.
32. Hsu H.C., Scott D.K., Mountz J.D. Impaired apoptosis and immune senescence cause or effect?. Immunol Rev 2005, 205:130-146.
33. Ikeda H., Chamoto K., Tsuji T., Suzuki Y., Wakita D., Takeshima T., et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004, 95:697-703.
34. O'Hagan D., De Gregorio E. The path to a successful vaccine adjuvant - 'the long and winding road'. Drug Discov Today 2009, 14:541-551.
35. Newman M.J., Balusubramanian M., Todd C.W. Development of adjuvant-active nonionic block copolymers. Adv Drug Deliv Rev 1998, 32:199-223.
36. Jeong B., Bae Y.H., Lee D.S., Kim S.W. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997, 388:860-862.
37. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006, 27:573-579.
38. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.